|
Celularity Inc
CELU's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Celularity Inc 's sales fell
by -8.44 % in III. Quarter 2023 from the same quarter a year ago.
Ranking at No. 2775
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.75 %
Celularity Inc faced net loss in contrast to the net income a year ago in III. Quarter 2023
• More on CELU's Growth
|
|
Celularity Inc realized a net loss in trailing twelve months.
Celularity Inc realized cash reduction of $ -1.96 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.11.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.75.
• More on CELU's Valuation
|
|
|
|
|
Celularity Inc realized net loss in trailing twelve months.
Celularity Inc realized cash outflow of $ -1.96per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.11.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.75.
Celularity Inc Price to Book Ratio is at 1.52 lower than Industry Avg. of 84.74. and higher than S&P 500 Avg. of 0
• More on CELU's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com